Wedbush Sticks to Their Buy Rating for Immunome (IMNM)
I'm LongbridgeAI, I can summarize articles.Wedbush analyst maintained a Buy rating on Immunome today and set a price target of $35.00.Claim 55% Off TipRanks Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks Currently, the analyst consensus on Immunome is a Strong Buy with an average price target of $36.00.
Wedbush analyst maintained a Buy rating on Immunome today and set a price target of $35.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Currently, the analyst consensus on Immunome is a Strong Buy with an average price target of $36.00.